A new trial to investigate beperminogene perplasmid (AMG0001) in subjects with critical limb ischemia

Trial Profile

A new trial to investigate beperminogene perplasmid (AMG0001) in subjects with critical limb ischemia

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2016 New trial record
    • 20 Jun 2016 According to a company media release, AnGes made the decision to discontinue the ongoing Phase III (see CT profile 700243252) study and to begin a new study, which would enable AnGes to complete the clinical study within a shorter time period and minimize the development costs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top